Who are Epicutaneous Immunotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Novel dose adjustment of Alutard SQ, immunotherapy Staloral, Zopapogene imadenovec (Zopa), BCG Solution, Diphtheria Antitoxin, Antiretroviral therapy plus Interleukin-2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epicutaneous-immunotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Epicutaneous Immunotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epicutaneous Immunotherapy (Epicutaneous Immunotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunotherapy. Area: Immunology.

phase 2 Immunotherapy Immunology Biologic Live · refreshed every 30 min

Target snapshot

Epicutaneous Immunotherapy (Epicutaneous Immunotherapy) — Assistance Publique - Hôpitaux de Paris. Allergen exposure to induce immune tolerance

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Epicutaneous Immunotherapy TARGET	Epicutaneous Immunotherapy	Assistance Publique - Hôpitaux de Paris	phase 2	Immunotherapy
Novel dose adjustment of Alutard SQ	Novel dose adjustment of Alutard SQ	Beijing Tongren Hospital	marketed	Allergen immunotherapy
immunotherapy Staloral	immunotherapy Staloral	Medical University of Silesia	marketed	Sublingual immunotherapy (SLIT)
Zopapogene imadenovec (Zopa)	Zopapogene imadenovec (Zopa)	Precigen, Inc	marketed	Oncolytic immunotherapy	Tumor cells (non-selective replication); immunostimulatory transgene product
BCG Solution	BCG Solution	Alliance for Clinical Trials in Oncology	marketed	Live attenuated vaccine / Immunotherapy
Diphtheria Antitoxin	Diphtheria Antitoxin	PT Bio Farma	marketed	Antitoxin (passive immunotherapy)	Diphtheria toxin
Antiretroviral therapy plus Interleukin-2	Antiretroviral therapy plus Interleukin-2	Juan A. Arnaiz	marketed	Combination immunotherapy and antiviral	HIV reverse transcriptase, protease, integrase (ART component); IL-2 receptor (IL-2 component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunotherapy class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Beijing Tiantan Hospital · 1 drug in this class
CytoVac A/S · 1 drug in this class
Hannover Medical School · 1 drug in this class
Pfizer · 1 drug in this class
The Cleveland Clinic · 1 drug in this class
Zarour, Hassane, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epicutaneous Immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/epicutaneous-immunotherapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing